Glass House Brands (GLAS) Change in Account Payables (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Change in Account Payables of $1.9 million for Q1 2026, up 416.01% year-over-year from $359486.6 in Q1 2025, and down 76.57% quarter-over-quarter from $7.9 million in Q4 2025.
Glass House Brands (GLAS) Change in Account Payables (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Change in Account Payables for 7 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 416.01% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $8.3 million (up 67.56% YoY), while the FY2025 annual figure was $5.8 million, down 30.86% from the prior year.
- Change in Account Payables retreated to $1.9 million in Q1 2026 per GLAS's latest filing, from $7.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $7.9 million in Q4 2025 and bottomed at -$5.8 million in Q3 2025.
- Historically, Change in Account Payables has averaged $1.7 million across 5 years, with a median of $2.2 million in 2023.
- On a YoY basis, Change in Account Payables climbed as much as 947.75% in 2025 and fell as far as 533.62% in 2025.
- Glass House Brands' Change in Account Payables stood at $214000.0 in 2022, then jumped by 927.93% to $2.2 million in 2023, then slumped by 142.46% to -$934000.0 in 2024, then surged by 947.75% to $7.9 million in 2025, then tumbled by 76.57% to $1.9 million in 2026.
- Business Quant data shows GLAS's Change in Account Payables at $1.9 million in Q1 2026, $7.9 million in Q4 2025, and -$5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Glass House Brands | 831.09 Mn | 812.54 Mn | 15.77 Mn | 6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Mar 31, 2025 | -587,000.00 |
| Mar 31, 2025 | -587,000.00 |
| Dec 31, 2024 | -934,000.00 |
| Dec 31, 2024 | -934,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Jun 30, 2024 | 7.37 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |